Sylvain Garciaz

11PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapyHaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 04, 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

|Apr 06, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

|Jun 06, 2025
Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1.

Sylvain Garciaz, Camille Montersino, Maxence Bourgoin

|Jun 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli

|Mar 28, 2024
Venetoclax Resistance in Acute Myeloid Leukemia.

Sylvain Garciaz, Marie-Anne Hospital, Yves Collette

|Nov 04, 2023
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Samia Harbi, Louison Brac de la Perriere, Benjamin Bouchacourt

Pageof 2

Frequent Collaborators

5 joint publications

Norbert Vey

5 joint publications

Christian Récher

3 joint publications

Sarah Bertoli

2 joint publications

David A Sallman